# Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia

> **NCT06933095** · NA · RECRUITING · sponsor: **University of Cincinnati** · enrollment: 153 (estimated)

## Conditions studied

- Eldery People
- Cognitive Decline
- Memory Decline
- DHA CNS Delivery

## Interventions

- **DIETARY_SUPPLEMENT:** LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)

## Key facts

- **NCT ID:** NCT06933095
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-15
- **Primary completion:** 2029-09-15
- **Final completion:** 2029-09-15
- **Target enrollment:** 153 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06933095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06933095, "Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06933095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*